Back to News
Market Impact: 0.28
Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial
Source: Nasdaq
Healthcare & Biotech
Clearmind Medicine announced that Yale University's Institutional Review Board approved patient recruitment for Parts B and C of its Phase I/II trial of CMND-100 for alcohol use disorder. The authorization advances the clinical-development program into additional patient-recruitment stages, but no efficacy, safety, or financial results were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
CMND0.72
More News
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Cholesterol drug setback casts doubt over multibillion-dollar race
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Stock Movers: SpaceX, Qualcomm, Roivant (Podcast)